Bruno Dalle

Bruno Dalle is an experienced professional in the pharmaceutical and biotechnology sectors, currently serving as the Head of CMC Development Quality at UCB since January 2021, responsible for ensuring product quality across the development portfolio. Previously, Bruno held various leadership roles at Yposkesi, including Head of Gene Therapy Quality and Quality Director, as well as at Genethon as Quality Director. Additional experience includes positions at Cellectis Stem Cells, MYOSIX, and Afssaps, where responsibilities encompassed Quality Assurance, Quality Control, and regulatory operations. Bruno's academic background includes a PostDoc from the Massachusetts Institute of Technology and a PhD from Université Paris Cité, complemented by a pharmacy doctorate from Paris-Sud University.